
SGMT Stock Forecast & Price Target
SGMT Analyst Ratings
Bulls say
Sagimet Biosciences is a promising biopharmaceutical company with a focus on developing innovative treatments for a range of diseases, including metabolic dysfunction-associated steatohepatitis (MASH), acne, and certain forms of cancer. Its drug candidate, denifanstat, has shown promising results in clinical trials for the treatment of acne and is expected to enter a Phase 3 trial later this year. Additionally, the company's second FASN inhibitor, TVB-3567, has the potential to be a more potent and effective treatment for acne. Overall, the company's pipeline and strategic focus on non-antibiotic, mechanism-based therapies suggest potential success in the highly competitive acne market. With a strong cash position and a solid clinical and regulatory risk profile, Sagimet Biosciences may have the potential for significant growth in the future.
Bears say
Sagimet Biosciences is facing potential risks including the possibility of denifanstat not demonstrating expected efficacy or safety in treating acne, potential failures of TVB-3567 or topical FASN inhibitor for acne treatment, and potential setbacks in clinical, regulatory, patent, or commercial aspects of their pipeline, all of which could lead to increased competition and hinder their success in the market.
This aggregate rating is based on analysts' research of Sagimet Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.
SGMT Analyst Forecast & Price Prediction
Start investing in SGMT
Order type
Buy in
Order amount
Est. shares
0 shares